ArticleBlood cancer journal2023
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Article
- Saga of MCL1 inhibitors in multiple myeloma.Biochemical pharmacology · 2026Review
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- [Prognostic value of high-risk cytogenetic abnormalities inmultiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- The past, present, and future of myeloma staging and risk prognostication.The oncologist · 2025Review
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.Nature cancer · 2025Article
- Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.Cancer medicine · 2025Article
- Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma.Cancers · 2025Article
- Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.Blood cancer journal · 2025Review
- Risk factors for multiple myeloma and its precursor diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Review
- A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma.Blood cancer journal · 2025Article
- A rare case of multiple myeloma with double translocations: t(11;14) and t(14;16).Journal of hematopathology · 2025Article
- Review
- [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.Blood cancer journal · 2024Article
- The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.Cancers · 2024Review
- The numerous facets of 1q21Oncology letters · 2024Review
- MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities.Haematologica · 2024Article
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.American journal of hematology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Anaïs SchavgoulidzeUnit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France.ORCID http://orcid.org/0000-0002-5526-4279
Aurore PerrotCancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Toulouse III-Paul Sabatier (UPS), Toulouse, France.ORCID http://orcid.org/0000-0003-0131-8689
Titouan CazaubielHematology Department, University Hospital, Bordeaux, France.
Xavier LeleuHematology Department, University Hospital, Poitiers, France.ORCID http://orcid.org/0000-0002-9822-4170
Lydia MontesHematology Department, University Hospital, Amiens, France.
Caroline JacquetHematology Department, University Hospital, Nancy, France.
Karim BelhadjHematology Department, University Hospital, Créteil, France.
Sabine BrechignacHematology Department, University Hospital, Bobigny, France.
Laurent FrenzelHematology Department, Necker University Hospital, Paris, France.
Thomas ChalopinHematology Department, University Hospital, Tours, France.
Philippe ReyHematology Department, Centre Léon Bérard, Lyon, France.
Jean-Marc Schiano de CollelaHematology Department, Institut Paoli Calmettes, Marseille, France.
Mamoun DibHematology Department, University Hospital, Angers, France.
Denis CaillotHematology Department, Institut de Cancérologie de Bourgogne, Dijon, France.
Margaret MacroHematology Department, University Hospital, Caen, France.
Jean FontanHematology Department, University Hospital, Besançon, France.
Laure BuissonUnit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France.
Luka PavageauUnit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France.
Murielle RousselHematology Department, University Hospital, Limoges, France.
Salomon ManierHematology Department, University Hospital, Lille, France.
Mohamad MohtyHematology Department, Saint-Antoine University Hospital, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X
Ludovic MartinetCancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Toulouse III-Paul Sabatier (UPS), Toulouse, France.
Hervé Avet-LoiseauUnit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France.
Jill CorreUnit for Genomics in Myeloma, University Hospital IUCT-Oncopole, Toulouse, France. corre.jill@iuct-oncopole.fr.ORCID http://orcid.org/0000-0003-1580-6106
Funding
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C. · 2003 to 2023
$45.0MTargeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5MNCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaChromosomes, Human, Pair 14HumansIn Situ Hybridization, FluorescencePrognosisTranslocation, Genetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.